These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
358 related articles for article (PubMed ID: 24335351)
1. EGFR signaling and autophagy dependence for growth, survival, and therapy resistance. Jutten B; Rouschop KM Cell Cycle; 2014; 13(1):42-51. PubMed ID: 24335351 [TBL] [Abstract][Full Text] [Related]
2. EGFR-mediated autophagy in tumourigenesis and therapeutic resistance. Wu M; Zhang P Cancer Lett; 2020 Jan; 469():207-216. PubMed ID: 31639425 [TBL] [Abstract][Full Text] [Related]
4. Targeting EGFR-mediated autophagy as a potential strategy for cancer therapy. Sooro MA; Zhang N; Zhang P Int J Cancer; 2018 Nov; 143(9):2116-2125. PubMed ID: 29574749 [TBL] [Abstract][Full Text] [Related]
6. Advances in Targeting the Epidermal Growth Factor Receptor Pathway by Synthetic Products and Its Regulation by Epigenetic Modulators As a Therapy for Glioblastoma. Nadeem Abbas M; Kausar S; Wang F; Zhao Y; Cui H Cells; 2019 Apr; 8(4):. PubMed ID: 31013819 [TBL] [Abstract][Full Text] [Related]
8. Acquired resistance of non-small cell lung cancer cells to MET kinase inhibition is mediated by a switch to epidermal growth factor receptor dependency. McDermott U; Pusapati RV; Christensen JG; Gray NS; Settleman J Cancer Res; 2010 Feb; 70(4):1625-34. PubMed ID: 20124471 [TBL] [Abstract][Full Text] [Related]
9. EGFR inhibitors and autophagy in cancer treatment. Cui J; Hu YF; Feng XM; Tian T; Guo YH; Ma JW; Nan KJ; Zhang HY Tumour Biol; 2014 Dec; 35(12):11701-9. PubMed ID: 25293518 [TBL] [Abstract][Full Text] [Related]
10. An activation of LC3A-mediated autophagy contributes to de novo and acquired resistance to EGFR tyrosine kinase inhibitors in lung adenocarcinoma. Nihira K; Miki Y; Iida S; Narumi S; Ono K; Iwabuchi E; Ise K; Mori K; Saito M; Ebina M; Sato I; Maemondo M; Yamada-Okabe H; Kondo T; Sasano H J Pathol; 2014 Oct; 234(2):277-88. PubMed ID: 24687913 [TBL] [Abstract][Full Text] [Related]
11. Human breast cancer cells harboring a gatekeeper T798M mutation in HER2 overexpress EGFR ligands and are sensitive to dual inhibition of EGFR and HER2. Rexer BN; Ghosh R; Narasanna A; Estrada MV; Chakrabarty A; Song Y; Engelman JA; Arteaga CL Clin Cancer Res; 2013 Oct; 19(19):5390-401. PubMed ID: 23948973 [TBL] [Abstract][Full Text] [Related]
12. Resistance mechanisms of tumour cells to EGFR inhibitors. Morgillo F; Cantile F; Fasano M; Troiani T; Martinelli E; Ciardiello F Clin Transl Oncol; 2009 May; 11(5):270-5. PubMed ID: 19451059 [TBL] [Abstract][Full Text] [Related]
13. Activated EGFR signaling increases proliferation, survival, and migration and blocks neuronal differentiation in post-natal neural stem cells. Ayuso-Sacido A; Moliterno JA; Kratovac S; Kapoor GS; O'Rourke DM; Holland EC; GarcĂa-Verdugo JM; Roy NS; Boockvar JA J Neurooncol; 2010 May; 97(3):323-37. PubMed ID: 19855928 [TBL] [Abstract][Full Text] [Related]
14. Cetuximab induces mitochondrial translocalization of EGFRvIII, but not EGFR: involvement of mitochondria in tumor drug resistance? Dreier A; Barth S; Goswami A; Weis J Tumour Biol; 2012 Feb; 33(1):85-94. PubMed ID: 21986964 [TBL] [Abstract][Full Text] [Related]
15. Targeting HER (ERBB) signaling in head and neck cancer: An essential update. Zhang J; Saba NF; Chen GZ; Shin DM Mol Aspects Med; 2015 Nov; 45():74-86. PubMed ID: 26163475 [TBL] [Abstract][Full Text] [Related]